Nabriva Therapeutics (STU:NTY) Total Liabilities : €24.83 Mil (As of Jun. 2023)

View and export this data going back to 2017. Start your Free Trial

What is Nabriva Therapeutics Total Liabilities?

Nabriva Therapeutics's Total Liabilities for the quarter that ended in Jun. 2023 was €24.83 Mil.

Nabriva Therapeutics's quarterly Total Liabilities declined from Dec. 2022 (€26.88 Mil) to Mar. 2023 (€26.80 Mil) and declined from Mar. 2023 (€26.80 Mil) to Jun. 2023 (€24.83 Mil).

Nabriva Therapeutics's annual Total Liabilities increased from Dec. 2020 (€20.80 Mil) to Dec. 2021 (€24.39 Mil) and increased from Dec. 2021 (€24.39 Mil) to Dec. 2022 (€26.88 Mil).

Nabriva Therapeutics Total Liabilities Historical Data

The historical data trend for Nabriva Therapeutics's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nabriva Therapeutics Total Liabilities Chart

Nabriva Therapeutics Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Total Liabilities

Get a 7-Day Free Trial

36.73

47.56

20.80

24.39

26.88

Nabriva Therapeutics Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
Total Liabilities	Get a 7-Day Free Trial															19.19	22.84	26.88	26.80	24.83

Nabriva Therapeutics Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Nabriva Therapeutics's Total Liabilities for the fiscal year that ended in Dec. 2022 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	26.059	+	(0.366	+	0.453
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	26.88

Total Liabilities	=	Total Assets (A: Dec. 2022 )	-	Total Equity (A: Dec. 2022 )
	=	29.986	-	3.109
	=	26.88

Nabriva Therapeutics's Total Liabilities for the quarter that ended in Jun. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	24.185	+	(0.318	+	0.325
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	24.83

Total Liabilities	=	Total Assets (Q: Jun. 2023 )	-	Total Equity (Q: Jun. 2023 )
	=	9.763	-	-15.064
	=	24.83

Nabriva Therapeutics Total Liabilities Related Terms

Thank you for viewing the detailed overview of Nabriva Therapeutics's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Nabriva Therapeutics (STU:NTY) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nabriva Therapeutics PLC (STU:NTY) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

NBRVF:USA

Address

Alexandra House, Office 225/227, The Sweepstakes, Dublin, IRL, 4

Website

https://www.nabriva.com

Nabriva Therapeutics PLC is a clinical stage biopharmaceutical company. Nabriva is engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The company has developed a product candidate, XENLETA, a semi-synthetic pleuromutilin antibiotic that is the first in its class for oral and IV administration in humans. XENLETA is designed to inhibit the synthesis of a specific protein on the bacterial ribosome. It operates in one reportable segment, which comprises the research and development of novel anti-infective agents to treat serious infections. The firm has commercial rights to two approved products, SIVEXTRO and XENLETA, as well as one development product candidate, CONTEPO.

Nabriva Therapeutics (STU:NTY) Headlines

No Headlines